Novo Nordisk Cuts Wegovy Sales Projections: The Impact of Compounding Issues Explained

Novo Nordisk’s stock took a significant hit recently, with shares dropping over 20%. The company announced that it expects sales growth for its obesity drug, Wegovy, to reach only 14% this year. This is a sharp decline from an earlier prediction of 21%.

The main reason for this change? Cheaper alternatives from compounding pharmacies. These pharmacies create medications similar to existing drugs when there’s a shortage. Wegovy, along with another drug called Ozempic, was recently included on a drug shortage list by the FDA, leading to a surge in demand for these alternatives.

Compounding pharmacies customize medications, tailoring them to individual patient needs. For example, if a patient struggles to swallow pills, a compounding pharmacist can provide a liquid version instead. While these drugs aren’t generics and don’t go through the same rigorous FDA approval process, they fulfill important roles for patients with specific requirements.

Novo Nordisk is actively trying to combat this trend. They’re pursuing several strategies to deal with the rise of compounded drugs, including potential legal action.

The company’s announcement also coincides with news of a leadership change. Maziar Mike Doustdar, a 33-year veteran at Novo Nordisk, will take over as CEO from Lars Jorgensen.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, argues that compounding pharmacists are being misrepresented by big pharma, including Novo Nordisk. He contends that compounding is entirely legal when tailored to meet patient needs.

Rena Conti, a health economist from Boston University, expressed that this situation isn’t unexpected. She notes a significant increase in compounding sales as these pharmacies ramp up marketing efforts. Competing company Eli Lilly has also been drawing users away from compounded drugs by directly selling their product, Zepbound, at a discount, particularly to those unable to use insurance. In fact, every month, around 100,000 people purchase Zepbound directly from Eli Lilly’s website.

As Novo Nordisk attempts to boost its Wegovy sales directly to consumers, the results have been underwhelming. They report that weekly prescriptions through their cash channel are much lower than anticipated.

In a rapidly changing market, Novo Nordisk is navigating challenges from both competition and evolving consumer preferences. Will they adapt successfully to regain their footing? Time will tell.

For further details, you can refer to the FDA and Novo Nordisk’s stock news.

Source link